Cite
MLA Citation
Takahisa Kawamura et al.. “Pharmacodynamic analysis of eribulin safety in breast cancer patients using real‐world postmarketing surveillance data.” Cancer science, vol. 109, no. 9, 2018, pp. 2822–2829. http://access.bl.uk/ark:/81055/vdc_100068497059.0x000021